For a better experience, Read this story in our App
TO ENJOY ADDITIONAL BENEFITS
Connect With Us
Get BusinessLine apps on
Source: Company website | Photo Credit: BL companies
Drug maker Lupin on Monday said it has entered into a licence and supply agreement with SteinCares for commercialisation of biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.
Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialisation of Ranibizumab in Latin America, while Lupin will be responsible for manufacturing the same, the Mumbai-based drug maker said in a statement.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A).
Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).
"Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients," Lupin President Biotechnology Cyrus Karkaria said.
Shares of Lupin were trading 0.32 per cent down at ₹1,972.80 apiece on BSE.
Published on May 26, 2025
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.